Mocravimod hydrochloride is under clinical development by Priothera and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According to GlobalData, Phase II drugs for Primary Mediastinal B-Cell Lymphoma have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Mocravimod hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Mocravimod hydrochloride overview

Mocravimod hydrochloride (KRP-203) is under development for the treatment of the autoimmune diseases like ulcerative colitis, subacute cutaneous lupus erythematosus, Acute Myeloid Leukemia (AML), secondary acute myeloid leukemia, primary mediastinal large b-cell lymphoma and Crohn’s disease and hematopoietic stem cell transplantation. The drug candidate is an orally administered immunosuppressant that acts by targeting S1P receptor. It was also under development for the treatment of the subacute cutaneous lupus erythematosus and ulcerative colitis and also for inflammatory bowel disease in Japan.

It was under development for the treatment of autoimmune diseases, inflammatory bowel disease, graft versus host disease (transplantation) and Crohn's disease. 

Priothera overview

Priothera is a clinical stage company developing orally applied sphingosine 1 phosphate (S1P) receptor modulators for haematological malignancies. Priothera is headquartered in Dublin, Ireland.

For a complete picture of Mocravimod hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.